Zosano Pharma Corporation (NASDAQ:ZSAN) Director Kenneth Greathouse bought 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was acquired at an average cost of $0.62 per share, with a total value of $31,000.00. Following the completion of the acquisition, the director now owns 35,000 shares of the company’s stock, valued at approximately $21,700. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Zosano Pharma Corporation (ZSAN) traded up $0.03 during mid-day trading on Friday, hitting $0.69. 667,271 shares of the company were exchanged, compared to its average volume of 603,830. Zosano Pharma Corporation has a 1 year low of $0.54 and a 1 year high of $3.54.

Zosano Pharma Corporation (NASDAQ:ZSAN) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05). research analysts predict that Zosano Pharma Corporation will post -0.79 EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/11/19/zosano-pharma-corporation-zsan-director-acquires-31000-00-in-stock.html.

Separately, ValuEngine raised shares of Zosano Pharma Corporation from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st.

An institutional investor recently raised its position in Zosano Pharma Corporation stock. Northern Trust Corp boosted its position in shares of Zosano Pharma Corporation (NASDAQ:ZSAN) by 591.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 79,234 shares of the biotechnology company’s stock after buying an additional 67,774 shares during the quarter. Northern Trust Corp owned 0.20% of Zosano Pharma Corporation worth $112,000 as of its most recent filing with the Securities & Exchange Commission. 22.67% of the stock is owned by institutional investors and hedge funds.

Zosano Pharma Corporation Company Profile

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

Receive News & Stock Ratings for Zosano Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corporation and related stocks with our FREE daily email newsletter.